PARP Inhibitors for Prostate Cancer with Moshe Ornstein, MD скачать в хорошем качестве

PARP Inhibitors for Prostate Cancer with Moshe Ornstein, MD

Moshe Ornstein, MD, Associate Staff, Hematology & Medical Oncology, Cleveland Clinic and Akhil Saklecha, MD, Managing Director, Ventures, Cleveland Clinic discuss PARP inhibitors for prostate cancer - #9 on the Top 10 Medical Innovations for 2021. About one man in nine will be diagnosed with prostate cancer in his lifetime. While optimism and progress in the last ten years have brought solace to some, the disease remains the second leading cause of cancer death among men in the US. PARP inhibitors, pharmacological inhibitors important in the treatment of cancer, block proteins called PARP that help repair damaged tumor DNA in people with BRCA1 and BRCA2 gene mutations. Though known for their success in women’s cancers, two PARP inhibitors have been demonstrated to delay the progression of prostate cancer in men with refractory cancer and BRCA mutations. Both were approved for the prostate cancer indication in May of 2020. For more information on the annual Top 10 Medical Innovations list including descriptions, videos, and year-by-year comparisons visit: https://innovations.clevelandclinic.o... ▶Share this video with others:    • PARP Inhibitors for Prostate Cancer with M...   ▶Subscribe to learn more about Cleveland Clinic: https://www.youtube.com/user/Clevelan...